GEN-MKT-18-7897-A
May 25, 2018 | Blogs, Food / Beverage | 0 comments
As hospitals struggle with increasingly hard-to-treat antimicrobial resistance (ARM) bacterial infections, related deaths now exceed 700,000 per year globally and are predicted to reach 10 million per year by 2050. There’s no denying that these statistics are both shocking and concerning, as existing antibiotics are increasingly losing their effectiveness.
While researchers work relentlessly to discover new classes of powerful antibiotics that could someday help to address a looming public health crisis, measures are being taken to restrict the impact of drug-resistant infections. AMR occurs naturally over time and is a complex issue with a multitude of factors to consider when it comes to quantifying causes and managing prevention. However, antibiotic resistance is accelerated by the misuse and overuse of antibiotics, and the link between animal ingestion of antibiotics and increasing resistance in humans is widely acknowledged.
Preventing Drug Residues Hitchhiking into the Food ChainVeterinary drug residues are making their way into the food chain, and human consumption of meat, fish, and crops is contributing to ARM, as well as other health epidemics such as hypersensitivity reactions and carcinogenicity. The use of antibiotics for livestock greatly exceeds the use for humans, and it is estimated that animal ingestion of antibiotics accounts for approximately 70-80 percent of total consumption worldwide. This is having a direct impact on human antibiotic intake.
Fortunately, there is a higher awareness of potential risks surrounding the (improper) use of veterinary drugs, and many countries have enforced legislation to restrict the usage of these substances. Agriculture will always include a level of necessary use for good animal welfare or to prevent crop failure, but the intention is to reduce veterinary drug residue levels in food products.
Multiclass Veterinary Drug Residue and Antibiotic AnalysisDetecting trace quantities of veterinary drug residues can be challenging for labs because they are complex, containing actives from a variety of chemical classes, such as antibiotics, antiparasitics, and non-steroidal anti-inflammatory drugs. While there are several analytical approaches available, few come close to mass spectrometry in delivering a fast and highly selective routine screening method.
High-resolution accurate mass spec technology from SCIEX is proven to identify and quantify very low levels of multiclass antibiotics and hormone residues across a comprehensive range of food samples:
SCIEX combines best-in-class mass spec hardware, software and support services to bring you an extensive solution for faster and simpler multi-residue detection. If you want to simplify your veterinary drug residue and antibiotic analysis workflows with an accurate method that analyzes low levels of analytes within complex matrices, look no further than the cutting edge high-resolution accurate mass spec solutions from SCIEX.Access a range of informative videos, webinars, tech sheets and other useful resources >
Regulated laboratories are evolving faster than ever. New analytical modalities, higher sample throughput, increasing regulatory scrutiny, and leaner teams are reshaping how work gets done. At the same time, expectations for data integrity, standardization, and operational efficiency continue to increase complexity and/or scope. In this environment, LC-MS software is no longer simply an instrument control platform—it has become a critical part of a laboratory’s quality management system. The question is no longer whether your lab has changed, but whether your software has evolved to support the way regulated labs operate today, and if they are ready and able to meet the demands, they will face tomorrow.
Analyst software has long been a trusted foundation in regulated LC-MS laboratories—and for many, it still performs reliably today. But regulated environments are evolving faster than ever. As labs transition to Windows 11, strengthen cybersecurity policies, modernize IT infrastructure, and prepare for future compliance expectations, software decisions are no longer just about what works today—they’re about managing tomorrow’s risk. Analyst will not be supported on Windows 11. While some labs may continue operating in unsupported environments temporarily, the bigger question is: when that risk becomes reality, will your lab be reacting under pressure—or executing a planned mitigation strategy with confidence?
As regulatory scrutiny increases and detection requirements tighten, laboratories are facing a new question: How can TFA be measured reliably, sensitively, and at scale?
Posted by
You must be logged in to post a comment.
Share this post with your network